GlassScriptPhysician profile
Donald J Phillips
NPI 1447485701
$4,647.35
in general payments reported to CMS, 2019-2025
15 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $18.20 · 2021: $764 · 2022: $1,615 · 2023: $23.60 · 2024: $1,641 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,300 · Food and Beverage: $538 · Travel and Lodging: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,300.00 |
| Food and Beverage | $537.52 |
| Travel and Lodging | $307.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuropace, INC. | $1,607.96 | 2024 | |
| Biocodex, INC. | $1,516.00 | 2022 | |
| Aquestive Therapeutics, INC. | $677.11 | 2021 | |
| Ucb, INC. | $300.52 | 2025 | |
| Sk Life Science, INC. | $225.89 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $77.16 | 2025 | |
| Neurocrine Biosciences, INC. | $63.75 | 2021 | |
| Acadia Pharmaceuticals INC | $56.38 | 2023-2024 | Daybue |
| Greenwich Biosciences, INC. | $34.12 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.00 | 2019-2020 | |
| Masimo Corporation | $28.32 | 2019 | |
| Livanova USA, INC. | $21.74 | 2019 | |
| Travere Therapeutics, INC. | $6.40 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.